1. The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
- Author
-
Adamson, Beth, Brittain, Nicholas, Walker, Laura, Duncan, Ruaridh, Luzzi, Sara, Rescigno, Pasquale, Smith, Graham, McGill, Suzanne, Burchmore, Richard J.S., Willmore, Elaine, Hickson, Ian, Robson, Craig N., Bogdan, Denisa, Jimenez-Vacas, Juan M., Paschalis, Alec, Welti, Jonathan, Yuan, Wei, McCracken, Stuart R., Heer, Rakesh, Sharp, Adam, de Bono, Johann S., and Gaughan, Luke
- Subjects
DNA -- Health aspects ,Prostate cancer -- Development and progression ,Cancer -- Genetic aspects ,Androgens -- Health aspects ,Enzymes -- Health aspects ,Genetic transcription -- Health aspects ,Health care industry - Abstract
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to full-length AR (AR-FL), AR-Vs constitutively activate androgenic signaling and are refractory to the current repertoire of AR-targeting therapies, which together drive disease progression. There is an unmet clinical need, therefore, to develop more durable PC therapies that can attenuate AR-V function. Exploiting the requirement of coregulatory proteins for AR-V function has the capacity to furnish tractable routes for attenuating persistent oncogenic AR signaling in advanced PC. DNA-PKcs regulates AR-FL transcriptional activity and is upregulated in both early and advanced PC. We hypothesized that DNA-PKcs is critical for AR-V function. Using a proximity biotinylation approach, we demonstrated that the DNA-PK holoenzyme is part of the AR-V7 interactome and is a key regulator of AR-V-mediated transcription and cell growth in models of advanced PC. Crucially, we provide evidence that DNA-PKcs controls global splicing and, via RBMX, regulates the maturation of AR-V and AR-FL transcripts. Ultimately, our data indicate that targeting DNA-PKcs attenuates AR-V signaling and provide evidence that DNA-PKcs blockade is an effective therapeutic option in advanced AR-V-positive patients with PC., Introduction Prostate cancer (PC) is the third most common malignancy worldwide. The androgen receptor (AR) is a member of the nuclear hormone receptor family of transcription factors that regulates a [...]
- Published
- 2023
- Full Text
- View/download PDF